TWi Biotechnology, Inc.
6610
Rank in Stocks
#18963
TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm,... TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the development and sale of medications designed to address innate immunity disorders, primarily within Taiwan. The company's drug pipeline notably includes AC-203, which is currently undergoing Phase 2 clinical trials for various conditions such as epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus. Additionally, AC-1101 is in Phase 1 trials for vitiligo treatment and is advancing through preclinical stages for atopic dermatitis, granuloma annulare, and other uncommon autoimmune skin diseases. TWi Biotechnology has also established a drug development collaboration with Hong Kong Winhealth Pharma Group Co., Limited, targeting the markets of Mainland China, Hong Kong, and Macao. Founded in 2010, the company is headquartered in Taipei, Taiwan.
Share Price
$0.52890536
Last synced: 2026-11-10
Market Cap
$117.90M
Change (1 day)
-2.53%
Change (1 year)
-54.28%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade TWi Biotechnology, Inc. (6610)
Category
Healthcare
EPS for TWi Biotechnology, Inc. (6610)
EPS as of June 2026 TTM: $-0.05
According to TWi Biotechnology, Inc.'s latest financial reports, its current EPS (TTM) is $-0.05. At the end of 2025 the company had an EPS of $-0.03, an increase over its 2024 EPS of $-0.05.
EPS history for TWi Biotechnology, Inc. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.05 | 50.33% |
| 2025 | $-0.03 | -38.59% |
| 2024 | $-0.05 | -24.83% |
| 2023 | $-0.07 | 94.31% |
| 2022 | $-0.04 | 367.09% |
| 2021 | $-0.01 | -84.69% |
| 2020 | $-0.05 | -3.01% |
| 2019 | $-0.05 | -9.06% |
| 2018 | $-0.06 | -3.15% |
| 2017 | $-0.06 | 6.53% |
| 2016 | $-0.06 | -22.86% |
| 2015 | $-0.07 | -7.89% |
| 2014 | $-0.08 | 42.75% |
| 2013 | $-0.06 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -34,822.84% |
US
|
|
| $-7.07 | 15,576.27% |
US
|
|
| $-5.29 | 11,629.49% |
AU
|
|
| $12.88 | -28,658.98% |
BE
|
|
| $21.56 | -47,904.88% |
NL
|
Questions about TWi Biotechnology, Inc.'s earnings per share (EPS)
What is TWi Biotechnology, Inc.'s earnings per share (EPS)?
TWi Biotechnology, Inc.'s earnings per share (EPS) over the last twelve months is $-0.05, as of Jun 2026.
What was TWi Biotechnology, Inc.'s earnings per share (EPS) in 2025?
In 2025, TWi Biotechnology, Inc.'s earnings per share (EPS) was $-0.03, compared with $-0.05 in 2024.
How has TWi Biotechnology, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, TWi Biotechnology, Inc.'s earnings per share (EPS) was highest in 2021 ($-0.01) and lowest in 2023 ($-0.07).
How does TWi Biotechnology, Inc.'s earnings per share (EPS) compare with similar companies?
TWi Biotechnology, Inc.'s earnings per share (EPS) ($-0.05) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.